Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Issue 3 (September 2021)
- Record Type:
- Journal Article
- Title:
- Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Issue 3 (September 2021)
- Main Title:
- Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)
- Authors:
- Sinha, Aditi
Southern, Kevin W. - Abstract:
- Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is an effective strategy for the early recognition of infants with a CF diagnosis. Some infants with a positive NBS result for CF have an inconclusive diagnosis and evidence suggests the number of these infants is increasing, as more extensive gene analysis is integrated into screening protocols. There is an internationally agreed, but complex, designation for infants with an unclear diagnosis after a positive screening result: cystic fibrosis transmembrane conductance regulator (CFTR)-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Infants with a CRMS/CFSPID designation have no clinical evidence of disease and do not meet the criteria for a CF diagnosis, but the NBS result indicates some risk of developing CF or a CFTR-related disorder. In this review, we describe the accurate designation of these and reflect on emerging management pathways, with particular attention given to clear and consistent communication. Educational aims: To clarify the definition of the global harmonised designation: cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS)/cystic fibrosis screen positive, inconclusive diagnosis (CFSPID). To understand what impact a CRMS/CFSPID result has for the patient and their family. There is an internationally agreed, but complex, designation for infants with an unclear diagnosis after a positive screening result:Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is an effective strategy for the early recognition of infants with a CF diagnosis. Some infants with a positive NBS result for CF have an inconclusive diagnosis and evidence suggests the number of these infants is increasing, as more extensive gene analysis is integrated into screening protocols. There is an internationally agreed, but complex, designation for infants with an unclear diagnosis after a positive screening result: cystic fibrosis transmembrane conductance regulator (CFTR)-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Infants with a CRMS/CFSPID designation have no clinical evidence of disease and do not meet the criteria for a CF diagnosis, but the NBS result indicates some risk of developing CF or a CFTR-related disorder. In this review, we describe the accurate designation of these and reflect on emerging management pathways, with particular attention given to clear and consistent communication. Educational aims: To clarify the definition of the global harmonised designation: cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS)/cystic fibrosis screen positive, inconclusive diagnosis (CFSPID). To understand what impact a CRMS/CFSPID result has for the patient and their family. There is an internationally agreed, but complex, designation for infants with an unclear diagnosis after a positive screening result: CRMS/CFSPID. The majority of CRMS/CFSPID infants remain well and do not convert to a diagnosis of CF. https://bit.ly/3mtpJTu … (more)
- Is Part Of:
- Breathe. Volume 17:Issue 3(2021)
- Journal:
- Breathe
- Issue:
- Volume 17:Issue 3(2021)
- Issue Display:
- Volume 17, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 17
- Issue:
- 3
- Issue Sort Value:
- 2021-0017-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-09
- Subjects:
- Respiratory organs -- Diseases
Respiratory organs -- Diseases -- Treatment
Periodicals
616.2005 - Journal URLs:
- https://breathe.ersjournals.com/content/by/year ↗
- DOI:
- 10.1183/20734735.0088-2021 ↗
- Languages:
- English
- ISSNs:
- 1810-6838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 24892.xml